News

Filter

Current filters:

Ibritumomab Tiuxetan

1 to 9 of 67 results

Cell Thera gets next $6.5M from Spectrum

09-04-2009

The USA's Cell Therapeutics has received the next $6.5 million of a total $16.5 million from its partner…

Ibritumomab TiuxetanZevalin

Spectrum's 2008 loss halves to $15.5M

03-04-2009

The USA's Spectrum Pharmaceuticals says that its 2008 net loss more than halved on the year before to…

Amino AcidsIbritumomab TiuxetanInjectionLevoleucovorinPhysostigmine SalicylateRituxanrituximabsumatriptanSumavel DoseProZevalin

Cell Thera sells Zevalin to partner Spectrum

02-03-2009

In what is seen by observers as a bid to keep the company financially afloat, Cell Therapeutics says…

Ibritumomab TiuxetanPaclitaxelTaxolZevalin

Spectrum and Cell Thera close deal for JV to market Zevalin

22-12-2008

US firms Spectrum Pharmaceuticals and Cell Therapeutics have closed their deal to form a 50/50 joint…

Ibritumomab TiuxetanZevalin

Spectrum and Cell Therapeutics form JV for projected expansion in US sales of Zevalin

08-12-2008

The USA's Spectrum Pharmaceuticals and Cell Therapeutics have formed a 50/50 joint venture to market…

AspirinBayerBayerBiogen IdecIbritumomab TiuxetanLevoleucovorinRituxanrituximabZevalin

Cell's Zevalin improves PFS in NHL patients

27-10-2008

USA-based Cell Therapeutics says that data from the FIT trial showed that Zevalin ([90Y]-ibritumomab…

Ibritumomab TiuxetanZevalin

Cell Thera submits sBLA for Zevalin as first-line therapy

06-10-2008

Seattle, USA-based Cell Therapeutics has submitted a supplemental Biologics License Application with…

AspirinBayerBayerIbritumomab TiuxetanZevalin

Cell Therapeutics recruits Craig Philips as president

18-08-2008

Craig Philips has assumed the post of president at US firm Cell Therapeutics, taking over from James…

AspirinBayerBayerIbritumomab TiuxetanZevalin

1 to 9 of 67 results

COMPANY SPOTLIGHT

Menarini

Back to top